Robert Caspari - Poniard Pharmaceuticals Ex Officer
| PARDDelisted Stock | USD 0.01 0.00 0.00% |
Insider
Robert Caspari is Ex Officer of Poniard Pharmaceuticals
| Age | 76 |
| Phone | 206 281 7001 |
| Web | https://www.poniard.com/ |
Poniard Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4603) % which means that it has lost $0.4603 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1037) %, meaning that it created substantial loss on money invested by shareholders. Poniard Pharmaceuticals' management efficiency ratios could be used to measure how well Poniard Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Poniard Pharmaceuticals currently holds 1.57 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Poniard Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Poniard Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Poniard Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poniard Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poniard to invest in growth at high rates of return. When we think about Poniard Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Alfredo Castro | Ikena Oncology | N/A | |
| Nicholas Keen | Bicycle Therapeutics | 56 | |
| MBA MBA | Scholar Rock Holding | 52 | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Evan Hecker | Ikena Oncology | N/A | |
| Klaus Frueh | Vir Biotechnology | 64 | |
| Stacey Davis | Xilio Development | N/A | |
| Martin MD | Xilio Development | 63 | |
| Gillian Langford | Bicycle Therapeutics | N/A | |
| Christian Heinis | Bicycle Therapeutics | N/A | |
| Christopher Carlson | Adaptive Biotechnologies Corp | N/A | |
| Ying Huang | Legend Biotech Corp | 51 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| MBA MD | Scholar Rock Holding | 57 | |
| Kevin MBA | Bicycle Therapeutics | 56 | |
| BCPS PharmD | Xilio Development | 47 | |
| Tycho Peterson | Adaptive Biotechnologies Corp | 50 | |
| CBE FMedsci | Bicycle Therapeutics | 71 | |
| Christopher Frankenfield | Xilio Development | 42 | |
| Nitin Sood | Adaptive Biotechnologies Corp | N/A | |
Management Performance
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 |
Poniard Pharmaceuticals Leadership Team
Elected by the shareholders, the Poniard Pharmaceuticals' board of directors comprises two types of representatives: Poniard Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poniard. The board's role is to monitor Poniard Pharmaceuticals' management team and ensure that shareholders' interests are well served. Poniard Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poniard Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Abrams, Ex Officer | ||
| Robert Caspari, Ex Officer |
Poniard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Poniard Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.1 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 434.76 K | ||||
| Shares Outstanding | 1.5 M | ||||
| Number Of Shares Shorted | 47.72 K | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 0.1 X | ||||
| EBITDA | (13.04 M) | ||||
| Net Income | (30.05 M) | ||||
| Cash And Equivalents | 1.98 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Correlations Find global opportunities by holding instruments from different markets |